UroGen Pharma (URGN) News Today $9.69 -1.26 (-11.51%) Closing price 04:00 PM EasternExtended Trading$9.90 +0.21 (+2.17%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lessened its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 69.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,114 shares of the company's stock after selling 46,948 shares during theMay 6 at 3:05 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of "Buy" from BrokeragesShares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have earned a consensus recommendation of "Buy" from the eight research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one hMay 6 at 2:21 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesMay 5 at 2:25 AM | americanbankingnews.comAcorn Capital Advisors LLC Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)Acorn Capital Advisors LLC purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,516,303 shares of the company's stock, valuedMay 4 at 7:12 AM | marketbeat.comHC Wainwright Comments on UroGen Pharma Q1 EarningsUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for UroGen Pharma in a research note issued on Monday, April 28th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.47)May 2, 2025 | marketbeat.comHC Wainwright Predicts UroGen Pharma Q1 EarningsMay 2, 2025 | americanbankingnews.comUroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 1, 2025 | businesswire.comGuggenheim Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research report on Tuesday.May 1, 2025 | marketbeat.comMarshall Wace LLP Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)Marshall Wace LLP bought a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,491 shares of the company's stock, valued at approxiMay 1, 2025 | marketbeat.comUroGen Pharma's (URGN) Buy Rating Reaffirmed at GuggenheimMay 1, 2025 | americanbankingnews.comUroGen Pharma (NASDAQ:URGN) Trading Up 10.8% - Here's What HappenedUroGen Pharma (NASDAQ:URGN) Trading 10.8% Higher - Here's What HappenedApril 30, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of UroGen Pharma in a report on Monday.April 30, 2025 | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for UroGen Pharma (NASDAQ:URGN)D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Monday.April 30, 2025 | marketbeat.comNantahala Capital Management LLC Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)Nantahala Capital Management LLC acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,371,638 shares of the company's stock, valued at approximately $14,608,0April 30, 2025 | marketbeat.comJump Financial LLC Lowers Position in UroGen Pharma Ltd. (NASDAQ:URGN)Jump Financial LLC lessened its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 69.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,185 shares of the company's stApril 30, 2025 | marketbeat.comRenaissance Technologies LLC Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN)Renaissance Technologies LLC purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 138,200 shares of the company's stock, valuApril 30, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Earns "Buy" Rating from HC WainwrightApril 30, 2025 | americanbankingnews.comUroGen Pharma announces results from Phase 1 study of UGN-301April 28, 2025 | markets.businessinsider.comAdage Capital Partners GP L.L.C. Has $31.18 Million Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Adage Capital Partners GP L.L.C. trimmed its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 21.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,928,086 shares of the company's sApril 28, 2025 | marketbeat.comUroGen Pharma announces long-term follow up data from OPTIMA II Phase 2b studyApril 28, 2025 | markets.businessinsider.comUroGen Pharma reports long-term follow-up study with JELMYTOApril 28, 2025 | markets.businessinsider.comOLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO TreatmentApril 27, 2025 | businesswire.comNew Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBCApril 27, 2025 | businesswire.comNew Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBCApril 27, 2025 | businesswire.comUroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)April 26, 2025 | businesswire.comUroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder CancerApril 26, 2025 | businesswire.comSilverarc Capital Management LLC Buys 219,344 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Silverarc Capital Management LLC raised its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 24.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,120,473 shares of the company's stock after purchasing aApril 24, 2025 | marketbeat.com50,000 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Diadema Partners LPDiadema Partners LP purchased a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,000 shares of the company's stock, valued at approximately $532,000. Diadema PartneApril 24, 2025 | marketbeat.comAlliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Alliancebernstein L.P. lifted its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 751.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 199,259 shares of the company's stock after acquiring an additional 1April 19, 2025 | marketbeat.comScotiabank Initiates Coverage on UroGen Pharma (NASDAQ:URGN)Scotiabank initiated coverage on UroGen Pharma in a research note on Wednesday. They issued a "sector outperform" rating and a $23.00 target price on the stock.April 18, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Ligand Pharma (LGND)April 17, 2025 | markets.businessinsider.comUroGen Pharma initiated with an Outperform at ScotiabankApril 17, 2025 | markets.businessinsider.comScotiabank Initiates Coverage of UroGen Pharma (URGN) with Sector Outperform RecommendationApril 17, 2025 | msn.comThis UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayApril 16, 2025 | benzinga.comExodusPoint Capital Management LP Acquires New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)ExodusPoint Capital Management LP bought a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 33,598 shares of the company's stock, valued at approximatelApril 15, 2025 | marketbeat.comUroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong BuyApril 12, 2025 | seekingalpha.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from AnalystsShares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have been given a consensus rating of "Buy" by the six brokerages that are covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. TApril 12, 2025 | marketbeat.comTrexquant Investment LP Has $1.84 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)Trexquant Investment LP cut its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 36.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 172,551 shares of the company's stock after selling 99,119April 11, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% - Here's WhyUroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% - What's Next?April 4, 2025 | marketbeat.comRosalind Advisors Inc. Makes New $9.27 Million Investment in UroGen Pharma Ltd. (NASDAQ:URGN)Rosalind Advisors Inc. purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 870,000 shares of the company's stock, valued at approximatMarch 23, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock Price Up 3.6% - Time to Buy?UroGen Pharma (NASDAQ:URGN) Trading 3.6% Higher - Still a Buy?March 21, 2025 | marketbeat.comPrivium Fund Management B.V. Purchases Shares of 27,691 UroGen Pharma Ltd. (NASDAQ:URGN)Privium Fund Management B.V. acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 27,691 shares of the company's stock, valued at approximately $295,March 20, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of "Buy" from AnalystsUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has received a consensus rating of "Buy" from the six brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the compaMarch 16, 2025 | marketbeat.comHC Wainwright Reduces Earnings Estimates for UroGen PharmaUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of UroGen Pharma in a research note issued on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.93) per share for the quarter,March 14, 2025 | marketbeat.comHC Wainwright Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $55.00HC Wainwright dropped their price objective on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday.March 12, 2025 | marketbeat.com34,701 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Purchased by Bender Robert & AssociatesBender Robert & Associates purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 34,701 shares of the company's stock, valued at approximately $370,000. Bender Robert & AssoMarch 12, 2025 | marketbeat.comUroGen Pharma price target lowered to $55 from $64 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comUroGen Pharma sees FY25 operating expenses $215M-$225MMarch 10, 2025 | markets.businessinsider.comUrogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch targetMarch 10, 2025 | msn.com Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼0.930.69▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼203▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kiniksa Pharmaceuticals News Today Tarsus Pharmaceuticals News Today Belite Bio News Today Beam Therapeutics News Today Vericel News Today Arrowhead Pharmaceuticals News Today Recursion Pharmaceuticals News Today Travere Therapeutics News Today Schrödinger News Today ImmunityBio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump's tariffs on China have caused a ripple effect across global markets. But in crypto? They've lit a fu...Crypto 101 Media | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy URGN Stock Free URGN Stock Alerts